Response to Comments: MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia

This document is a Response to Comments regarding MolDX LCD L39256 (Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia). The public comment period occurred 03/31/2022–05/14/2022; the notice period begins 03/30/2023 and the LCD is effective 05/14/2023. No clinical coverage criteria, claim documentation requirements, or frequency limits are provided in this notice and require review of the underlying LCD L39256 for clinical details.

"Notice that the MolDX LCD L39256 comment period ran 03/31/2022–05/14/2022; the notice period for L39256 begins 03/30/2023 and the LCD becomes effective 05/14/2023."

Sign up to see full coverage criteria, indications, and limitations.